KRAS mutations, long recognized as critical drivers in various cancers, have been notoriously difficult to target effectively. Recent advances in small molecule inhibitors have enabled direct targeting of mutant KRAS proteins, offering new hope particularly for colorectal cancer patients harboring these mutations. However, clinical trials revealed an emerging pattern of resistance, with tumors rapidly adapting and resuming growth despite continuous KRAS inhibition. The study’s authors set out to decipher the molecular underpinnings that empower tumors to resist these once-promising agents.

At the core of their discovery lies the mevalonate pathway, a critical metabolic cascade responsible for producing sterols, isoprenoids, and other essential biomolecules involved in cell membrane integrity, protein prenylation, and cell signaling. Intriguingly, the research demonstrates that colorectal cancer cells, when faced with blockade of KRAS signaling, undergo profound enhancer remodeling — epigenetic and chromatin-based changes that rewire gene regulatory elements — which in turn upregulates components of the mevalonate pathway. This adaptive metabolic shift not only compensates for the inhibited KRAS activity but also fuels continued tumor cell survival and proliferation.

Utilizing state-of-the-art epigenomic profiling techniques, including ATAC-seq and ChIP-seq, the investigators mapped dynamic changes in enhancer landscapes in colorectal tumors subjected to KRAS inhibitor treatment. Their data reveal a robust activation of enhancers associated with key mevalonate pathway genes, correlating with increased transcriptional output. These enhancer regions exhibit hallmark features of activation, such as heightened H3K27ac marks, underscoring the tumor’s epigenetic plasticity as a driving force behind therapeutic resistance.

The functional consequences of mevalonate pathway enrichment were explored through comprehensive metabolomic and lipidomic analyses. Cancer cells demonstrated elevated levels of cholesterol, farnesyl pyrophosphate, and geranylgeranyl pyrophosphate—metabolites critical for post-translational modification of signaling proteins, including small GTPases beyond KRAS itself. This suggests that the tumor’s metabolic flexibility allows bypassing of blocked KRAS signaling by fostering alternative prenylation-dependent oncogenic pathways, sustaining malignant phenotypes.

Crucially, pharmacological inhibition of enzymes within the mevalonate pathway, such as HMG-CoA reductase, in combination with KRAS inhibitors, reversed resistance and significantly impaired tumor growth in preclinical colorectal cancer models. These findings pave the way for novel combinatorial therapeutic strategies that target both signaling and metabolic axes, potentially transforming current clinical management of KRAS-mutant colorectal cancer.

The implications of enhancer remodeling driven metabolic rewiring extend beyond colorectal cancer. Given the prevalence of KRAS mutations across multiple tumor types, similar adaptive resistance mechanisms may underlie therapeutic failure in lung and pancreatic cancers treated with KRAS inhibitors. This highlights the imperative to integrate epigenomic and metabolic profiling in future clinical trials to identify biomarkers predictive of resistance and optimize treatment regimens.

At a molecular level, enhancer remodeling involves recruitment and redistribution of transcription factors and coactivators, altering chromatin accessibility landscapes. The study identifies key players such as BRD4 and the histone acetyltransferase p300 as facilitators of enhancer activation at mevalonate pathway loci. Targeting these epigenetic modulators with BET inhibitors or HAT inhibitors demonstrated partial restoration of KRAS inhibitor sensitivity, providing additional therapeutic avenues.

This research underscores the complexity of cancer resistance, reinforcing the concept that tumor cells can co-opt fundamental biological processes—such as epigenetic regulation and metabolic flux—to evade targeted therapies. It exemplifies the necessity of multidimensional therapeutic interventions that concurrently address both genetic drivers and adaptive cellular states.

Moreover, the study emphasizes the evolving role of advanced genomic and epigenomic technologies in oncology research. The integration of enhancer landscape mapping with metabolic profiling creates a powerful framework for uncovering hidden resistance pathways. This systems biology approach will be crucial to staying one step ahead of cancer evolution and therapeutic evasion.

In conclusion, the elucidation of mevalonate pathway rewiring driven by enhancer remodeling as a mechanism conferring resistance to KRAS inhibitors represents a major leap in our understanding of colorectal cancer biology. It advocates for the development of combination therapies that strategically target interconnected oncogenic networks. Future clinical trials incorporating inhibitors of both the KRAS signaling axis and mevalonate metabolism hold promise for overcoming resistance and improving patient outcomes.

As the war against cancer advances into new terrain, studies like this reveal the adaptive ingenuity of tumor cells and the sophisticated molecular arms race that defines modern oncology. By illuminating these concealed survival tactics, researchers provide both a warning and a beacon—resistance is inevitable, but so too is the potential for innovative solutions grounded in deep mechanistic insight.

The road ahead demands close collaboration between basic scientists, clinicians, and pharmaceutical developers to translate these insights into effective therapies. Precision oncology is entering an era where epigenetic and metabolic plasticity are recognized as central determinants of therapeutic success. Understanding and targeting these dynamic cellular programs will be key to achieving durable remissions in KRAS-mutant colorectal cancer and beyond.

Subject of Research: Resistance mechanisms in colorectal cancer involving mevalonate pathway rewiring and enhancer remodeling under KRAS inhibitor treatment.

Article Title: Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer.

Article References:
Guo, Y., Zhong, Y., Hu, P. et al. Mevalonate pathway rewiring driven by enhancer remodelling confers resistance to KRAS inhibitors in colorectal cancer. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73805-7

Image Credits: AI Generated

Traditional inhibitors function by binding to mutant KRAS proteins and obstructing their activity, but this method often falls short as cancer cells evolve mechanisms to circumvent inhibition and resume proliferative signaling. Addressing this limitation, the new study pivots towards inducing the selective degradation of the mutant KRAS protein itself, rather than merely inhibiting its function. This strategy leverages Proteolysis Targeting Chimeras (PROTACs), an innovative drug class designed to co-opt the cell’s intrinsic protein degradation machinery, effectively “tagging” the oncogenic protein for proteasomal destruction.

However, no current PROTACs can directly engage KRAS^G12V, posing a significant challenge. To overcome this, the research team ingeniously engineered lung cancer cells to express KRAS^G12V appended with a molecular tag amenable to novel PROTACs developed in collaboration with chemical biology experts at IRB Barcelona. This innovative tagging allowed the precise recruitment of the degradation system, resulting in efficient elimination of the mutant KRAS protein in vivo.

Employing genetically modified mouse models harboring these tagged KRAS^G12V proteins, the researchers observed remarkable tumor regression upon PROTAC treatment. The lung adenocarcinomas regressed substantially, highlighting the tumor cells’ profound dependency on continuous KRAS^G12V signaling for survival and proliferation. This response was more robust and durable compared to outcomes previously reported with conventional KRAS inhibitors, suggesting that targeted proteolysis could represent a superior therapeutic avenue.

Intriguingly, the study also delineated the immune landscape following KRAS degradation. Although an increase in immune cell infiltration within treated tumors was documented, parallel experiments in immunodeficient mice confirmed that the initial tumor regression was predominantly driven by direct cancer cell-autonomous mechanisms rather than the immune system. This insight emphasizes the fundamental cytotoxic potential of mutant KRAS degradation, independent of adaptive immune activation.

Delving deeply into the mechanisms of acquired resistance, the scientists uncovered a resistance paradigm distinct from that encountered with kinase inhibitors. Instead of mutations within KRAS itself or reactivation of downstream oncogenic pathways, resistant tumors exhibited alterations in the cellular proteostasis machinery. These modifications impaired the effectiveness of the proteasomal degradation system, effectively sabotaging the molecular machinery required to dismantle mutant KRAS, thereby allowing the tumor cells to evade destruction.

This distinct resistance mechanism highlights an evolutionary pressure on tumors to preserve KRAS dependence while simultaneously overcoming the novel therapeutic approach. By dysregulating protein degradation pathways, cancer cells develop an unexpected mode of resistance, underscoring the complexity of targeted proteolysis as a therapeutic modality and the necessity for combination strategies or next-generation PROTACs that can circumvent this escape route.

The conception and execution of this work are the result of a highly collaborative endeavor, integrating expertise from molecular biology, chemical synthesis, and cancer pharmacology across institutions including IRB Barcelona, Centro de Investigación del Cáncer, University of Salamanca, University of Navarra, Catalan Institute of Oncology, University of Liège, University of Turin, CIBERONC, and University of Barcelona. The interdisciplinary nature of this research reinforces the value of collaborative networks in tackling the formidable challenge of KRAS-driven malignancies.

From a therapeutic development perspective, these findings signal the dawn of a new era in targeted cancer therapies. While KRAS inhibitors revolutionized treatment paradigms, the advent of targeted protein degradation represents a paradigm shift with potential transformative impacts on clinical outcomes. The prospect of deploying sequential or combinatorial regimens, integrating KRAS inhibition with degradation, could potentiate tumor control and circumvent the resistance that plagues monotherapy approaches.

Moreover, the tailored strategy of tagging mutant KRAS not only facilitates in vivo functional studies of KRAS degradation dynamics but also establishes a versatile platform to explore PROTAC efficacy against other oncogenic drivers traditionally deemed “undruggable.” This platform empowers future preclinical investigations and accelerates the translation of proteolysis-based therapeutics into clinical settings for diverse cancer types.

Support for this pioneering research was generously provided by the Spanish Ministry of Science and Innovation, the European Research Council (ERC), the Spanish Association Against Cancer (AECC), Generalitat de Catalunya, the European Union’s NextGenerationEU program, “la Caixa” Foundation, and Farmaindustria. Their commitment underscores the critical societal imperative of advancing cancer research toward curative therapies.

In summary, the strategic targeting of mutant KRAS through induced degradation via PROTAC technology represents a compelling advance, combining molecular innovation with therapeutic promise. This elegant approach not only deepens understanding of lung adenocarcinoma biology but also charts new directions for combating resistance, potentially heralding a future where devastating KRAS-driven cancers can be durably controlled or eradicated.

Subject of Research: Targeted degradation of mutant KRAS in lung adenocarcinoma using PROTAC technology and investigation of resistance mechanisms in vivo.

Article Title: Targeted KRASG12V degradation in vivo elicits lung adenocarcinoma regression with subsequent relapse from dysregulated proteolysis

News Publication Date: 27 May 2026

Image Credits: IRB Barcelona

Keywords: Lung cancer, KRAS mutation, oncogene, targeted protein degradation, PROTACs, drug resistance, lung adenocarcinoma, immunotherapy, cancer treatment, proteolysis, in vivo study, molecular tag

It is well established that virtually all PDAC cases arise from activating mutations in the KRAS gene. These mutations produce a constitutively active KRAS protein that drives uncontrolled cell proliferation via downstream signaling cascades such as RAF–MEK–ERK. Notably, clinical efforts to directly inhibit mutant KRAS, especially the KRAS^G12C variant, have seen limited success because the G12C mutation is exceptionally rare in PDAC and tumors rapidly develop resistance to these inhibitors. This presents a formidable challenge, as KRAS remains a critical oncogenic driver with limited therapeutic options.

Exploring the broader landscape of KRAS oncogenic activity, recent investigations have shifted attention towards the cyclin D1-CDK4/6-RB1 axis. Oncogenic KRAS promotes transcriptional upregulation of cyclin D1, which forms an active complex with CDK4/6, leading to phosphorylation and inactivation of RB1. The RB1 protein, a pivotal gatekeeper of cell cycle progression, suppresses proliferation by inhibiting E2F family transcription factors. When RB1 is phosphorylated by cyclin D1-CDK4/6, it becomes functionally disabled, releasing E2F to drive the cell cycle forward.

This antagonistic relationship between KRAS and RB1 is not merely a one-way street. RB1, when active, suppresses a critical post-translational modification— isoprenylation—required for KRAS trafficking to the Golgi apparatus and subsequent activation. Thus, activated RB1 restricts KRAS signaling by impeding its activation cycle. This mutual antagonism establishes a dynamic equilibrium, ensuring that activation of one molecule suppresses the other. Interestingly, while KRAS mutations overwhelmingly dominate PDAC tumorigenesis, mutations in RB1 are rare, implying that RB1 remains largely wild-type and functional in these cancers.

Leveraging this insight, researchers hypothesized that pharmacologic activation of RB1 might indirectly suppress oncogenic KRAS signaling, providing a novel, indirect therapeutic avenue. CDK4/6 inhibitors, already clinically approved for certain breast cancers, inhibit the kinase activity necessary for RB1 phosphorylation, thereby sustaining RB1 in its active, hypophosphorylated state. In theory, this would restore RB1’s tumor suppressive function and counter KRAS-driven malignancy.

Initial investigations into CDK4/6 inhibitor monotherapy for PDAC indeed demonstrated efficacy in inducing cellular senescence—a state of permanent cell cycle arrest with a distinct secretory profile. However, this monotherapy failed to trigger sufficient tumor cell death to produce meaningful clinical benefit. Drawing parallels to breast cancer treatment, where CDK4/6 inhibitors are combined with estrogen receptor blockers, attention turned to identifying synergistic combination therapies to augment antitumor effects.

A pivotal breakthrough came with the identification of ERK inhibitors as potent agents that selectively induced death in PDAC cells harboring an activated RB1 state—mimicking the effects of CDK4/6 inhibition. Counterintuitively, despite expectations that ERK activity would diminish downstream of KRAS suppression by CDK4/6 inhibitors, a robust and sustained ERK reactivation was observed. This paradoxical ERK signaling hinted at an adaptive resistance mechanism dampening the effectiveness of CDK4/6 inhibitors.

Further mechanistic studies revealed that the source of this ERK reactivation was upstream activation of the epidermal growth factor receptor (EGFR) pathway. Upon CDK4/6 inhibition and induction of senescence, PDAC cells exhibited a senescence-associated secretory phenotype (SASP), characterized by secretion of a spectrum of autocrine and paracrine factors, notably EGFR ligands. These ligands potently stimulate EGFR and consequently reactivate ERK signaling via a mechanism likely independent of RAS itself. This EGFR-mediated survival signaling cascade also promotes downstream pro-survival pathways, including those governed by BCL2 and NF-kB, collectively conferring resistance to CDK4/6 inhibitor-induced cell death.

This mechanistic insight inspired a strategic combination approach targeting both CDK4/6 and EGFR signaling axes. Leveraging clinically available EGFR inhibitors, researchers combined CDK4/6 inhibitors with either gefitinib, an EGFR tyrosine kinase inhibitor, or cetuximab, an anti-EGFR monoclonal antibody. Remarkably, these combinations demonstrated potent antitumor efficacy in vitro and in vivo, including in human PDAC xenograft models and genetically engineered mice prone to spontaneous pancreatic cancer development.

Beyond synergistic tumor suppression, this combination therapy exposed an intriguing therapeutic concept: senolysis, the selective elimination of senescent cells. PDAC cells initially entered senescence upon CDK4/6 inhibitor exposure; subsequent EGFR blockade selectively triggered cell death within this senescent population. Notably, this senolytic effect required precise sequencing, as pre-treatment with EGFR inhibitors prior to CDK4/6 inhibition failed to produce similar therapeutic benefits. This underscores the critical importance of treatment scheduling in exploiting the vulnerabilities of senescent cancer cells.

A major concern with senolytic strategies is the potential off-target elimination of normal cells entering senescence, which could result in tissue toxicity. Addressing this, researchers employed sophisticated mouse models expressing reporter constructs for p16, a hallmark of senescence, enabling live tracking of senescent cells in vivo. Encouragingly, CDK4/6 inhibitor treatment did not induce detectable senescence in normal tissues, supporting a favorable therapeutic window and strengthening the translational potential of this combinatorial regimen.

While EGFR inhibitors are traditionally reserved for tumors harboring activating EGFR mutations, PDAC generally lacks such alterations. This limitation is circumvented by the use of anti-EGFR monoclonal antibodies—such as cetuximab—which are efficacious regardless of EGFR mutational status. Consequently, combining CDK4/6 inhibitors with anti-EGFR antibodies represents a pragmatic, immediately translatable clinical strategy for PDAC and potentially other tumors dependent on similar signaling crosstalk.

The implications of this research transcend pancreatic cancer. The paradigm of exploiting the mutual antagonism between oncogenic drivers and tumor suppressors, coupled with exploiting therapy-induced senescence and subsequent senolysis, may revolutionize treatment approaches for various recalcitrant cancers. Moreover, the reliance on already approved agents accelerates the pathway to clinical evaluation, opening avenues for rapid implementation in investigator-initiated trials.

In conclusion, this transformative study elucidates a novel therapeutic vulnerability in PDAC grounded in the reciprocal inhibitory dynamics between KRAS and RB1. Through rational combination therapy employing CDK4/6 inhibitors to activate RB1, paired with EGFR pathway blockade to overcome adaptive resistance, an effective and clinically practicable strategy emerges against one of the deadliest malignancies. This milestone exemplifies how dissecting molecular intricacies can yield powerful therapeutic innovations with far-reaching clinical impact.

Subject of Research: Therapeutic strategies targeting KRAS-driven pancreatic ductal adenocarcinoma via the CDK4/6-RB1 axis and EGFR signaling.

Article Title: Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6 inhibition

News Publication Date: 18-Dec-2025

Web References: DOI: 10.1038/s41418-025-01634-0

References: Takahashi C. et al., Nature Genetics 38, 113–128 (2006); Takahashi C. et al., Cancer Cell 15, 255–269 (2009); Zhang Y. et al., Cell Death and Differentiation (2025).

Image Credits: Chiaki TAKAHASHI

Keywords: Pancreatic Cancer, KRAS Mutation, RB1 Tumor Suppressor, CDK4/6 Inhibitors, EGFR Signaling, Cellular Senescence, Senolysis, ERK Reactivation, Therapeutic Resistance, Combination Therapy